La empresa de Cosmo ha finalizado la fase II para el CB-03-01 del acné:
Cosmo announces successful conclusion of acne Phase II trial and agreement with Valeant to continue developing CB-03-01 in house
Lainate, Italy – July 8, 2014 – Cosmo Pharmaceuticals S.p.A. (SIX: COPN) today informed that it had successfully concluded the phase II acne trials of CB-03-01 and that, prior to the upcoming end of phase II meeting with the FDA, both Cosmo and Valeant Pharmaceuticals International, Inc., the licensee (NYSE / TSX: VRX), had agreed that it was preferable for both parties for Cosmo to continue developing the drug. Consequently both Cosmo and Valeant agreed to unwind the present agreement and replace it with an agreement granting Valeant a right of first refusal should Cosmo decide to license out the drug after completing its development.Alessandro Della Chà, CEO, commented: “I am very pleased by the results of this phase II, and even more pleased that Cosmo can continue developing the products in-house, leveraging on all the accumulated know how. Their potential is very significant, so the retention of the rights now allow us to create a stronger franchise in the derma field. Together with CB-03-01 we now have 5 products in clinical development. Given our strong financial position and in-house expertise, we are well equipped to exploit the potential of this rich pipeline for the benefit of patients and shareholders”."
Además, parece ser que Cosmo tiene una nueva compañía de investigación subsidiaria, lo que en teoría supondría un mayor poder económico y de medios para llevar hasta el final las investigaciones y desarrollo de el CB-03-01 para la ALOPECIA.
http://www.cosmopharmaceuticals.com/new ... 07-09.aspx